MARKET

IRMD

IRMD

IRadimed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.62
+0.51
+2.31%
After Hours: 22.62 0 0.00% 16:00 10/23 EDT
OPEN
22.31
PREV CLOSE
22.11
HIGH
22.96
LOW
22.25
VOLUME
35.76K
TURNOVER
--
52 WEEK HIGH
28.43
52 WEEK LOW
14.42
MARKET CAP
276.93M
P/E (TTM)
52.63
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Analysts Estimate iRadimed (IRMD) to Report a Decline in Earnings: What to Look Out for
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 1d ago
iRadimed Earlier Reported Q2 EPS $0.05 Down From $0.20 YoY, Sales $6.80M Beat $6.44M Estimate
iRadimed (NASDAQ:IRMD) reported quarterly earnings of $0.05 per share. This is a 75 percent decrease over earnings of $0.20 per share from the same period last year. The company reported quarterly sales of $6.80 million
Benzinga · 07/30 12:56
IRadimed (IRMD) Beats Q2 Earnings and Revenue Estimates
iRadimed (IRMD) delivered earnings and revenue surprises of 225.00% and 22.96%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/30 12:45
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 07/30 12:09
iRadimed EPS misses by $0.10, beats on revenue
Seeking Alpha · 07/30 11:04
IRADIMED CORPORATION Announces Second Quarter 2020 Financial Results
* Reports second quarter 2020 revenue of $6.8 million, GAAP diluted EPS of $(0.17) and non-GAAP diluted EPS of $0.05 * Reports combined cash and investments of $47.8 million as of June 30, 2020WINTER SPRINGS, Fla., July 30, 2020 (GLOBE NEWSWIRE) -- iRadimed
GlobeNewswire · 07/30 11:00
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Benzinga · 07/26 13:55
Earnings Preview: iRadimed (IRMD) Q2 Earnings Expected to Decline
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/23 16:32
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IRMD. Analyze the recent business situations of IRadimed through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IRMD stock price target is 28.00 with a high estimate of 30.00 and a low estimate of 26.00.
EPS
Institutional Holdings
Institutions: 95
Institutional Holdings: 5.55M
% Owned: 45.34%
Shares Outstanding: 12.24M
TypeInstitutionsShares
Increased
32
594.54K
New
22
-15.87K
Decreased
16
140.89K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.07%
Healthcare Equipment & Supplies
+0.12%
Key Executives
Chairman/President/Chief Executive Officer/Founder/Chief Technology Officer/Director
Roger Susi
Chief Financial Officer/Secretary
Chris Scott
Vice President/Director of Sales
MaryBeth Smith
Vice President
Steven Kachelmeyer
Vice President
Steve Nardi
Vice President
Fran Casey
Vice President - Research & Development
Lynn Neuhardt
Independent Director
Monty Allen
Independent Director
James Hawkins
Independent Director
Anthony Vuoto
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About IRMD
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, non-ferrous part and other features in order to deliver anesthesia and other IV fluids during various MRI procedures. MRI compatible IV infusion pump system includes the 3860+ MRI compatible IV infusion pump, single-use IV tubing sets, a non-magnetic pole and a lithium battery. In addition, it offers optional upgrade systems, including the 3865 Remote Display/Control, 3861 Side Car, Dose Error Reduction System (DERS) and SpO2 monitor.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Iradimed Corp stock information, including NASDAQ:IRMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IRMD stock methods without spending real money on the virtual paper trading platform.